Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson's disease.

Aging / genetics Animals Calcium Channels, R-Type / genetics Calcium Signaling Cation Transport Proteins / genetics Cell Survival / genetics Dopaminergic Neurons / metabolism Humans Induced Pluripotent Stem Cells Mice Mice, Knockout Neuronal Calcium-Sensor Proteins / genetics Neuropeptides / genetics Parkinson Disease / genetics Substantia Nigra / metabolism Up-Regulation Ventral Tegmental Area / metabolism

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
08 11 2019
Historique:
received: 31 10 2017
accepted: 27 09 2019
entrez: 10 11 2019
pubmed: 11 11 2019
medline: 4 3 2020
Statut: epublish

Résumé

Degeneration of dopaminergic neurons in the substantia nigra causes the motor symptoms of Parkinson's disease. The mechanisms underlying this age-dependent and region-selective neurodegeneration remain unclear. Here we identify Cav2.3 channels as regulators of nigral neuronal viability. Cav2.3 transcripts were more abundant than other voltage-gated Ca

Identifiants

DOI: 10.1038/s41467-019-12834-x PMID: 31704946 PMC: PMC6841684
pubmed: 31704946
doi: 10.1038/s41467-019-12834-x
pii: 10.1038/s41467-019-12834-x
pmc: PMC6841684
doi:

Substances chimiques

Cacna1e protein, mouse 0
Calcium Channels, R-Type 0
Cation Transport Proteins 0
Neuronal Calcium-Sensor Proteins 0
Neuropeptides 0
frequenin calcium sensor proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5094

Subventions

Organisme : Parkinson's UK
ID : H-1202
Pays : United Kingdom
Organisme : Parkinson's UK
ID : H-1102
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M024962/1
Pays : United Kingdom
Organisme : Austrian Science Fund FWF
ID : P 27809
Pays : Austria
Organisme : Parkinson's UK
ID : J-0901
Pays : United Kingdom
Organisme : Parkinson's UK
ID : K-1412
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_EX_MR/N50192X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom

Références

Philos Trans R Soc Lond B Biol Sci. 2015 Jul 5;370(1672):
pubmed: 26009764
Cell Calcium. 2016 Jan;59(1):12-20
pubmed: 26691915
Curr Opin Neurobiol. 2019 Aug;57:46-53
pubmed: 30769276
Nat Neurosci. 2018 Oct;21(10):1300-1309
pubmed: 30258237
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:263-289
pubmed: 30625283
Elife. 2018 Dec 17;7:
pubmed: 30556810
J Neurosci. 2017 Mar 29;37(13):3704-3720
pubmed: 28264982
Annu Rev Physiol. 2018 Feb 10;80:219-241
pubmed: 28938084
Cold Spring Harb Perspect Biol. 2019 May 1;11(5):
pubmed: 30833454
Ann Clin Transl Neurol. 2017 May 09;4(6):360-368
pubmed: 28589163
FEBS J. 2018 Oct;285(19):3591-3603
pubmed: 29385658
Brain. 2014 Aug;137(Pt 8):2287-302
pubmed: 24934288
Pharmacol Rev. 2015 Oct;67(4):821-70
pubmed: 26362469
Hum Mol Genet. 2019 Jun 15;28(12):2001-2013
pubmed: 30753527
Nat Commun. 2019 Apr 18;10(1):1817
pubmed: 31000720
Front Mol Neurosci. 2019 Nov 27;12:252
pubmed: 31827421
Nat Rev Neurosci. 2017 Jan 20;18(2):101-113
pubmed: 28104909
Nat Cell Biol. 2007 Apr;9(4):453-60
pubmed: 17369816
Neuroscience. 2014 Dec 12;282:13-22
pubmed: 24463000
Biophys J. 2001 Jul;81(1):79-88
pubmed: 11423396
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a009316
pubmed: 22229125
J Neurochem. 2016 Oct;139 Suppl 1:325-337
pubmed: 27577098
Sci Rep. 2017 Jul 12;7(1):5248
pubmed: 28701749
FEBS J. 2009 Apr;276(7):1800-16
pubmed: 19243429
Brain. 1999 Aug;122 ( Pt 8):1437-48
pubmed: 10430830
Exp Neurol. 2017 Dec;298(Pt B):202-209
pubmed: 28780195
Nature. 2010 Dec 2;468(7324):696-700
pubmed: 21068725
J Neurosci. 1984 Nov;4(11):2866-76
pubmed: 6150070
J Neurochem. 2016 Oct;139 Suppl 1:77-90
pubmed: 26860875
Mov Disord. 2012 Oct;27(12):1478-83
pubmed: 23008164
Ann Neurol. 1998 Sep;44(3 Suppl 1):S89-98
pubmed: 9749579
Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt B):1660-1667
pubmed: 29746899
Stem Cell Reports. 2018 Nov 13;11(5):1171-1184
pubmed: 30344006
Curr Biol. 2015 Sep 21;25(18):2349-60
pubmed: 26320949
Ann Neurol. 2010 May;67(5):600-6
pubmed: 20437557
Nat Commun. 2014 Jun 06;5:4028
pubmed: 24905578
J Neurosci. 2014 Jul 9;34(28):9310-8
pubmed: 25009264
J Neurosci. 2016 Jul 6;36(27):7234-45
pubmed: 27383597
J Neurosci. 2001 May 15;21(10):3443-56
pubmed: 11331374
J Parkinsons Dis. 2011;1(1):19-33
pubmed: 23275799
Mov Disord. 2017 Sep;32(9):1264-1310
pubmed: 28887905
J Neurosci. 2014 Oct 8;34(41):13586-99
pubmed: 25297088
J Neurodegener Dis. 2016;2016:5780809
pubmed: 27516917
J Neurosci. 2009 Sep 2;29(35):11011-9
pubmed: 19726659
J Neurosci. 2002 May 1;22(9):3404-13
pubmed: 11978817
Nat Neurosci. 2014 Jun;17(6):832-40
pubmed: 24816140
J Neurosci. 2017 Jul 12;37(28):6761-6777
pubmed: 28592699
Front Neurol. 2018 Jun 19;9:455
pubmed: 29971039
Pharmaceuticals (Basel). 2013 May 27;6(6):759-76
pubmed: 24276260
Front Mol Neurosci. 2019 Mar 22;12:55
pubmed: 30967759
J Biol Chem. 2010 Feb 12;285(7):4405-14
pubmed: 20018864
Epilepsia. 2006 May;47(5):839-50
pubmed: 16686648
J Neurosci. 2017 Jan 4;37(1):47-57
pubmed: 28053029
Eur J Pharmacol. 2016 Oct 5;788:274-279
pubmed: 27364758
Cell Tissue Res. 2018 Jul;373(1):9-20
pubmed: 29536161
EMBO J. 2001 Oct 15;20(20):5715-24
pubmed: 11598014
J Clin Invest. 2018 Jun 1;128(6):2266-2280
pubmed: 29708514
Mol Endocrinol. 2002 Apr;16(4):884-95
pubmed: 11923483
Sci Rep. 2015 Sep 18;5:13688
pubmed: 26381090
Front Cell Neurosci. 2019 Feb 21;13:27
pubmed: 30846929
Neuron. 2003 Sep 11;39(6):889-909
pubmed: 12971891
Hum Mol Genet. 2017 Feb 1;26(3):552-566
pubmed: 28096185
Front Neuroanat. 2014 Dec 15;8:155
pubmed: 25565980
J Neurosci. 2014 Jul 9;34(28):9182-9
pubmed: 25009251
J Physiol. 2015 Feb 15;593(4):929-46
pubmed: 25533038
Ann Neurol. 2010 Jun;67(6):715-25
pubmed: 20517933
J Histochem Cytochem. 2000 Jun;48(6):807-19
pubmed: 10820154
Cell Stem Cell. 2019 Jan 3;24(1):93-106.e6
pubmed: 30503143
Science. 2017 Sep 22;357(6357):1255-1261
pubmed: 28882997
Br Med Bull. 2015 Jun;114(1):39-52
pubmed: 25995343
Nat Neurosci. 2012 Oct;15(10):1414-21
pubmed: 22941107
Neuron. 2008 Mar 13;57(5):760-73
pubmed: 18341995
J Neurochem. 2016 Oct;139 Suppl 1:156-178
pubmed: 26865375

Auteurs

Julia Benkert (J)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Simon Hess (S)

Institute for Zoology, Biocenter, CECAD, University of Cologne, Cologne, Germany.

Shoumik Roy (S)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Dayne Beccano-Kelly (D)

Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.

Nicole Wiederspohn (N)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Johanna Duda (J)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Carsten Simons (C)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.
ORCID: 0000-0003-3936-5181

Komal Patil (K)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Aisylu Gaifullina (A)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Nadja Mannal (N)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Elena Dragicevic (E)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Desirée Spaich (D)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Sonja Müller (S)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Julia Nemeth (J)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.
ORCID: 0000-0002-9277-0736

Helene Hollmann (H)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Nora Deuter (N)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Yassine Mousba (Y)

Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
ORCID: 0000-0002-0676-332X

Christian Kubisch (C)

Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Christina Poetschke (C)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Joerg Striessnig (J)

Department of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria.

Olaf Pongs (O)

Institute of Physiology, CIPMM, University of the Saarland, Homburg, Germany.

Toni Schneider (T)

Institute for Neurophysiology, University of Cologne, Cologne, Germany.
ORCID: 0000-0003-2816-2696

Richard Wade-Martins (R)

Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.

Sandip Patel (S)

Department of Cell and Developmental Biology, UCL, London, UK.

Rosanna Parlato (R)

Institute of Applied Physiology, University of Ulm, Ulm, Germany.

Tobias Frank (T)

Department of Neurology, University Medicine Göttingen, Göttingen, Germany.

Peter Kloppenburg (P)

Institute for Zoology, Biocenter, CECAD, University of Cologne, Cologne, Germany.

Birgit Liss (B)

Institute of Applied Physiology, University of Ulm, Ulm, Germany. birgit.liss@uni-ulm.de.
New College, University of Oxford, Oxford, UK. birgit.liss@uni-ulm.de.
ORCID: 0000-0002-6733-9207

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Vieillissement › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Eucaryotes › Animaux › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Canaux ioniques › Canaux calciques › Canaux calciques de type N › Canaux calciques de type R › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Systèmes de seconds messagers › Signalisation calcique › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Pompes ioniques › Transporteurs de cations › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Cellules › Neurones › Neurones dopaminergiques › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches pluripotentes › Cellules souches pluripotentes induites › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines neuronales sensibles au calcium › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Neuropeptides › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladie de Parkinson › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Mésencéphale › Pédoncule cérébral › Substantia nigra › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation positive › Cav2.3 channels contribute to dopaminergic...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Mésencéphale › Pédoncule cérébral › Tegmentum du mésencéphale › Aire tegmentale ventrale › Cav2.3 channels contribute to dopaminergic...